R. Bailly, R. Bosselut, J. Zucman, F. Cormier, O. Delattre et al., DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma., Molecular and Cellular Biology, vol.14, issue.5, pp.3230-3241, 1994.
DOI : 10.1128/MCB.14.5.3230

D. Dauphinot-l, C. Oliveira, T. Melot, N. Sevenet, V. Thomas et al., Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression, Oncogene, vol.20, issue.25, pp.3258-3265, 2001.
DOI : 10.1007/BF02281873

M. Fukuma, H. Okita, J. Hata, and A. Umezawa, Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma, Oncogene, vol.22, issue.1, pp.1-9, 2003.
DOI : 10.1038/17812

Y. Matsumoto, K. Tanaka, F. Nakatani, T. Matsunobu, S. Matsuda et al., Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G1regulatory genes, British Journal of Cancer, vol.84, issue.6, pp.768-775, 2001.
DOI : 10.1054/bjoc.2000.1652

E. Beauchamp, G. Bulut, O. Abaan, K. Chen, A. Merchant et al., GLI1 Is a Direct Transcriptional Target of EWS-FLI1 Oncoprotein, Journal of Biological Chemistry, vol.269, issue.14, pp.9074-9082, 2009.
DOI : 10.1158/0008-5472.CAN-07-0491

B. Braun, R. Frieden, W. Sl, and C. Denny, Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis., Molecular and Cellular Biology, vol.15, issue.8, pp.4623-4630, 1995.
DOI : 10.1128/MCB.15.8.4623

B. Fuchs, C. Inwards, and R. Janknecht, Vascular Endothelial Growth Factor Expression is Up-Regulated by EWS-ETS Oncoproteins and Sp1 and May Represent an Independent Predictor of Survival in Ewing's Sarcoma, Clinical Cancer Research, vol.10, issue.4, pp.1344-1353, 2004.
DOI : 10.1158/1078-0432.CCR-03-0038

A. Nagano, T. Ohno, K. Shimizu, A. Hara, T. Yamamoto et al., EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A, International Journal of Cancer, vol.23, pp.2790-2798, 2010.
DOI : 10.4161/cbt.2.2.348

URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.24781/pdf

M. Mendiola, J. Carrillo, E. Garcia, E. Lalli, T. Hernandez et al., The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors, International Journal of Cancer, vol.16, issue.6, pp.1381-1389, 2006.
DOI : 10.1210/me.16.3.515

URL : https://hal.archives-ouvertes.fr/hal-00172274

E. Garcia-aragoncillo, J. Carrillo, E. Lalli, N. Agra, G. Gomezlopez et al., DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells, Oncogene, vol.275, issue.46, pp.6034-6043, 2008.
DOI : 10.1128/MCB.17.3.1476

. Christensen-l, J. Joo, S. Lee, D. Wai, T. Triche et al., FOXM1 Is an Oncogenic Mediator in Ewing Sarcoma, PLoS ONE, vol.103, issue.1, p.54556, 2013.
DOI : 10.1371/journal.pone.0054556.s004

G. Richter, S. Plehm, A. Fasan, S. Rossler, R. Unland et al., EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation, Proceedings of the National Academy of Sciences, vol.4, issue.5, pp.5324-5329, 2009.
DOI : 10.1038/nm0598-627

K. Hahm, K. Cho, C. Lee, Y. Im, J. Chang et al., Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FlI1 oncoprotein, Nat Genet, vol.23, pp.222-227, 1999.

F. Nakatani, K. Tanaka, R. Sakimura, Y. Matsumoto, T. Matsunobu et al., as a Direct Target of EWS-Fli1 Oncogenic Fusion Protein, Journal of Biological Chemistry, vol.278, issue.17, pp.15105-15115, 2003.
DOI : 10.1111/j.1749-6632.1999.tb09415.x

Y. Im, H. Kim, C. Lee, D. Poulin, S. Welford et al., EWS-FlI1, EWS-ERG, and EWS- ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene, Cancer Res, vol.60, pp.1536-1540, 2000.

A. Prieur, F. Tirode, P. Cohen, and O. Delattre, EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3, Molecular and Cellular Biology, vol.24, issue.16, pp.7275-7283, 2004.
DOI : 10.1128/MCB.24.16.7275-7283.2004

H. Kovar, Downstream EWS/FLI1 - upstream Ewing's sarcoma, Genome Medicine, vol.2, issue.1, p.8, 2010.
DOI : 10.1186/gm129

URL : https://genomemedicine.biomedcentral.com/track/pdf/10.1186/gm129?site=genomemedicine.biomedcentral.com

K. Tanaka, T. Iwakuma, K. Harimaya, H. Sato, and Y. Iwamoto, EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells., Journal of Clinical Investigation, vol.99, issue.2, pp.239-247, 1997.
DOI : 10.1172/JCI119152

D. Hewings, T. Rooney, J. Le, D. Hay, C. Schofield et al., Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain???Acetyl-lysine Interactions, Journal of Medicinal Chemistry, vol.55, issue.22, pp.9393-9413, 2012.
DOI : 10.1021/jm300915b

R. Prinjha, J. Witherington, and K. Lee, Place your BETs: the therapeutic potential of bromodomains, Trends in Pharmacological Sciences, vol.33, issue.3, pp.146-153, 2012.
DOI : 10.1016/j.tips.2011.12.002

Z. Yang, N. He, and Q. Zhou, Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression, Molecular and Cellular Biology, vol.28, issue.3, pp.967-976, 2008.
DOI : 10.1128/MCB.01020-07

URL : http://mcb.asm.org/content/28/3/967.full.pdf

P. Bandopadhayay, G. Bergthold, B. Nguyen, S. Schubert, S. Gholamin et al., BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma, Clinical Cancer Research, vol.20, issue.4, pp.912-925, 2014.
DOI : 10.1158/1078-0432.CCR-13-2281

J. Delmore, G. Issa, M. Lemieux, P. Rahl, J. Shi et al., BET Bromodomain Inhibition as??a Therapeutic Strategy to Target c-Myc, Cell, vol.146, issue.6, pp.904-917, 2011.
DOI : 10.1016/j.cell.2011.08.017

URL : https://doi.org/10.1016/j.cell.2011.08.017

M. Dawson, R. Prinjha, A. Dittmann, G. Giotopoulos, M. Bantscheff et al., Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia, Nature, vol.461, issue.7370, pp.529-533, 2011.
DOI : 10.1038/nature08448

J. Zuber, J. Shi, E. Wang, A. Rappaport, H. Herrmann et al., RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia, Nature, vol.41, issue.7370, pp.524-528, 2011.
DOI : 10.2144/000112297

T. Komori, Runx2, A multifunctional transcription factor in skeletal development, Journal of Cellular Biochemistry, vol.97, issue.1, pp.1-8, 2002.
DOI : 10.1073/pnas.180309597

S. Pande, G. Browne, S. Padmanabhan, S. Zaidi, J. Lian et al., Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells, Journal of Cellular Physiology, vol.71, issue.8, pp.1784-1792, 2013.
DOI : 10.1158/0008-5472.CAN-10-2603

A. Beesley, A. Stirnweiss, E. Ferrari, R. Endersby, M. Howlett et al., Comparative drug screening in NUT midline carcinoma, British Journal of Cancer, vol.16, issue.5, pp.1189-1198, 2014.
DOI : 10.1038/nature10334

URL : http://www.nature.com/bjc/journal/v110/n5/pdf/bjc201454a.pdf

W. Fiskus, S. Sharma, J. Qi, B. Shah, S. Devaraj et al., BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD, Molecular Cancer Therapeutics, vol.13, issue.10, pp.2315-2327, 2014.
DOI : 10.1158/1535-7163.MCT-14-0258

T. Shimamura, Z. Chen, M. Soucheray, J. Carretero, E. Kikuchi et al., Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.19, issue.22, pp.6183-6192, 2013.
DOI : 10.1158/1078-0432.CCR-12-3904

. Se, D. Price, and W. Figg, BET bromodomain inhibitors?a novel epigenetic approach in castrationresistant prostate cancer, Cancer Biol Ther, vol.15, pp.1583-1585, 2014.

J. Loven, H. Hoke, C. Lin, A. Lau, D. Orlando et al., Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers, Cell, vol.153, issue.2, pp.320-334, 2013.
DOI : 10.1016/j.cell.2013.03.036

D. Hnisz, J. Schuijers, C. Lin, A. Weintraub, B. Abraham et al., Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers, Molecular Cell, vol.58, issue.2, pp.362-370, 2015.
DOI : 10.1016/j.molcel.2015.02.014

E. Tomazou, N. Sheffield, C. Schmidl, M. Schuster, A. Schonegger et al., Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1, Cell Reports, vol.10, issue.7, pp.1082-1095, 2015.
DOI : 10.1016/j.celrep.2015.01.042

P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W. Smith et al., Selective inhibition of BET bromodomains, Nature, vol.4, issue.7327, pp.1067-1073, 2010.
DOI : 10.1016/S0002-9440(10)63049-0

T. Hensel, C. Giorgi, O. Schmidt, J. Calzada-wack, F. Neff et al., Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma, Oncotarget, vol.7, issue.2, pp.1451-63, 2016.
DOI : 10.18632/oncotarget.6385

S. Hu-lieskovan, J. Heidel, D. Bartlett, M. Davis, and T. Triche, Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma, Cancer Research, vol.65, issue.19, pp.8984-8992, 2005.
DOI : 10.1158/0008-5472.CAN-05-0565

W. Whyte, D. Orlando, D. Hnisz, B. Abraham, C. Lin et al., Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes, Cell, vol.153, issue.2, pp.307-319, 2013.
DOI : 10.1016/j.cell.2013.03.035

URL : https://doi.org/10.1016/j.cell.2013.03.035

J. Zwerner, J. Joo, W. Kl, . Christensen-l, S. Hulieskovan et al., The EWS/FLI1 oncogenic transcription factor deregulates GLI1, Oncogene, vol.79, issue.23, pp.3282-3291, 2008.
DOI : 10.1038/sj.onc.1204133

URL : http://www.nature.com/onc/journal/v27/n23/pdf/1210991a.pdf

C. Chandhanayingyong, Y. Kim, J. Staples, C. Hahn, and F. Lee, MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions, Sarcoma, vol.39, issue.2, p.404810, 2012.
DOI : 10.1111/j.1365-2559.2005.02266.x

URL : https://doi.org/10.1155/2012/404810

R. Silvany, S. Eliazer, N. Wolff, I. Rl, and J. , Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation, Oncogene, vol.19, issue.39, pp.4523-4530, 2000.
DOI : 10.1200/JCO.1996.14.4.1245

P. Grohar, G. Woldemichael, G. Mendoza, A. Chen, Q. Yeung et al., Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening, JNCI: Journal of the National Cancer Institute, vol.31, issue.4, pp.962-978, 2011.
DOI : 10.1002/1097-0142(197304)31:4<889::AID-CNCR2820310419>3.0.CO;2-H

H. Erkizan, Y. Kong, M. Merchant, S. Schlottmann, J. Barber-rotenberg et al., A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma, Nature Medicine, vol.105, issue.7, pp.750-756, 2009.
DOI : 10.1038/nm.1983

P. Grohar, G. Yeung, C. Chen, Q. Pommier, Y. Khanna et al., Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells, Neoplasia, vol.13, issue.2, pp.145-153, 2011.
DOI : 10.1593/neo.101202

S. Pott, What are super-enhancers?, Nature Genetics, vol.8, issue.1, pp.8-12, 2015.
DOI : 10.1126/science.1247005

E. Beauchamp, G. Bulut, K. Sajwan, M. Hall, Y. Lee et al., Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway, Journal of Clinical Investigation, vol.121, issue.1, pp.148-160, 2011.
DOI : 10.1172/JCI42874DS1

A. Sengupta, M. Rahman, S. Mateo-lozano, O. Tirado, and V. Notario, The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing???s sarcoma, International Journal of Oncology, vol.43, issue.3, pp.803-812, 2013.
DOI : 10.3892/ijo.2013.2016

M. Kinsey and R. Smith, NR0B1 Is Required for the Oncogenic Phenotype Mediated by EWS/FLI in Ewing's Sarcoma, Molecular Cancer Research, vol.4, issue.11, pp.851-859, 2006.
DOI : 10.1158/1541-7786.MCR-06-0090

K. Yudoh, M. Kanamori, K. Ohmori, T. Yasuda, M. Aoki et al., Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas, British Journal of Cancer, vol.84, issue.12, pp.1610-1615, 2001.
DOI : 10.1054/bjoc.2001.1837